Global Bio-chem Technology Group Co. Ltd.

Global Bio-chem Technology Group Co. Ltd.

HHKEX:809
0.35
HKD
+0.01
(+1.45%)
1.09BMarket Cap
Global Bio-chem Technology Group Co. Ltd.
HKEX:809
(Hong Kong Exchange)

Recent

price

0.35

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
HKD
33.89
43.95
36.5
29.68
19.61
8.52
6.07
6.87
8.84
6.64
1
0.84
0.01
1.54
2.24
0.21
- -
Revenue per Share
1.21
4.03
-1.7
-18.63
-10.31
-5.07
-2.89
-1.31
-1.91
-1.55
-2.86
-0.45
-1.62
4.74
0.86
0.01
- -
Basic EPS, GAAP
-7
0.49
- -
1.1
1.4
-0.96
-0.49
-0.11
-0.36
0.51
-0.05
-0.56
-0.11
-0.11
0.09
- -
- -
Free Cash Flow per Basic Share
0.02
0.25
0.2
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
26.79
31.22
29.63
12.99
2.5
-0.23
-2.82
-3.76
-5.39
-5.47
-6.58
-7.32
-8.46
-4.53
-4.15
-1.34
-1.34
Book Value per Share
25.63
28
26.37
9.43
0.02
-0.94
-3.73
-4.74
-6.29
-5.47
-6.58
-7.32
-8.47
-4.53
-4.15
-1.34
-1.34
Tangible Book Value per Share
275
325
326
326
326
393
640
640
640
687
851
891
891
891
893
10,818
931
Basic Weighted Avg Shares
9,315
14,299
11,908
9,687
6,399
3,352
3,883
4,397
5,658
4,561
849
747
13
1,374
2,001
2,279
- -
Sales/Revenue/Turnover
9.25
16.12
0.81
-23.12
-26.86
-22.39
-6.69
-2.99
-12.79
-13.32
-40.38
-51.24
-2,045.72
-23.76
-4.79
-3.45
- -
Operating Margin (%)
524
618
668
846
621
613
497
420
503
505
457
403
331
305
229
114
- -
Depreciation Expense
332
1,310
-555
-6,081
-3,365
-1,996
-1,851
-837
-1,222
-1,068
-2,430
-401
-1,443
4,225
770
156
- -
Net Income, GAAP
22.79
19.58
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.07
- -
Effective Tax Rate (%)
3.56
9.16
-4.66
-62.78
-52.59
-59.55
-47.66
-19.05
-21.6
-23.41
-286.26
-53.69
-11,352.91
307.48
38.46
6.86
- -
Profit Margin (%)
2,865
2,520
1,376
-394
-5,263
-2,501
-3,597
-5,715
-7,724
-8,877
-11,118
-11,443
-12,818
-7,426
-4,386
-2,325
-2,325
Working Capital
4,224
3,607
4,807
4,798
2,682
4,371
5,049
4,469
2,842
2,047
1,034
941
- -
812
- -
560
560
LT Debt
9,673
11,863
11,238
5,081
1,251
24
-1,804
-2,467
-3,571
-4,346
-6,017
-6,701
-7,787
-4,037
-1,954
-519
-519
Total Equity
4.03
9.43
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
75.38
- -
Return on Invested Capital (%)
3.55
8.45
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
47.04
- -
Return on Capital (%)
4.1
13.87
-5.59
-87.44
-133.16
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

HKD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
2,653
2,294
1,233
LT Borrowings
- -
557
560
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
1,727
1,727
1,727
Shares Outstanding
888
886
1,679
Market Capitalization
941
807
1,091

Working Capital

HKD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
2,100
2,219
2,243
Cash, Cash Equivalents & STI
85
138
94
Accounts Receivable, Net
159
103
163
Inventories
206
274
45
Total Current Liabilities
6,486
6,328
4,568
Payables & Accruals
- -
- -
- -
ST Debt
2,653
2,294
1,233
Deferred Revenue
- -
- -
- -

Growth Rates

HKD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-759.72%
-29.13%
-73.47%
Free Cash Flow
44.79%
133.11%
-137.33%
Net Income, GAAP
-27.88%
-75.54%
-79.69%
Sales/Revenue/Turnover
1,061.52%
2,131.64%
13.86%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
1,374
2024
- -
- -
2,001
2025
- -
- -
2,279

Semi-annual Earnings Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
4.74
2024
- -
- -
0.86
2025
- -
- -
0.01

Semi-annual Dividends Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Business
Global Bio-chem Technology Group Company Limited (0809.HK) is an investment holding company principally engaged in the manufacture and sale of corn refined products and corn-based biochemical products. The company operates through three main segments: Amino Acids, offering lysine, threonine, tryptophan, 98% lysine, and 65% protein lysine for animal feed and other applications; Upstream Products, producing corn starch, corn fiber, gluten meal, corn oil, and other corn refined by-products; and Corn Sweeteners and Polyol Chemicals, including glucose, maltose, high fructose corn syrup, maltodextrin, crystallized glucose, modified starch, polyol chemicals, anti-freeze products, hydrogen, and ammonia. These products serve diverse industries such as animal feed production, food and beverages, cosmetics, textiles, pharmaceuticals, and chemicals, with production facilities primarily located in Changchun and Dehui, Jilin Province, Northeast China. Founded in 1994 and headquartered in Hung Hom, Kowloon, Hong Kong, the company maintains its largest corn refining operations in Asia, with an annual processing capacity historically reaching 2.4 million metric tonnes by 2008, and markets its products in the People's Republic of China, rest of Asia, the Americas, and internationally. It holds a leading position as one of the world's largest producers of lysine series products in the fermentation industry and pioneered commercial polyol chemical production from corn. The company is owned by parent Changchun Dacheng Industry Group and previously spun off its sweeteners business as subsidiary Global Sweeteners Holdings Limited in 2007. In recent developments, Global Bio-chem has focused on financial restructuring and operational enhancements, including the resumption of relevant properties expected to generate proceeds for debt settlement during 2024 and 2025, and the completion of a Debt-to-Equity-Swap Agreement with Suppliers PRC LLPs to improve its balance sheet. The group secured financial support from indirect major shareholder Nongtou Group (Jilin Province Agricultural Investment Group), which acquired a significant stake and provides stable corn supply under a master agreement effective December 2023, alongside commitments for operational funding over the next 12 months. Additionally, it continues to maximize amino acids production capacity, launching high value-added products to boost cash inflows in 2024, while progressing debt repurchases from entities like Jilin Cinda and implementing cost-saving measures amid challenging market conditions.